Hemab Therapeutics names Keli Walbert to board, adds her to audit committee
Bitget2026/09/24 20:01- Hemab Therapeutics appointed Keli Walbert to its board, effective Sept. 24, 2026.
- Walbert will join the board’s Audit Committee, replacing Akshay Vaishnaw.
- Walbert most recently served as executive vice president of U.S. commercial at Horizon Therapeutics.
- Her background includes commercial leadership roles at AbbVie, the American Medical Association, Abbott, United Healthcare.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Bank of Japan's interest rate hike still fails to impress the market! Hedge funds slash yen long positions by nearly 80%, while dollar long positions increase significantly
After the Bank of Japan failed to deliver a clear enough signal of further interest rate hikes to the market, hedge funds have significantly reduced their bullish bets on the yen.
US Treasury yields continue to rise! Cleveland Federal Reserve President: Government and AI compete for funds, fueling rate hike expectations
Cleveland Federal Reserve President Loretta Mester stated on Friday that the recent sustained rise in long-term U.S. Treasury yields is the result of multiple factors working together.
Crypto prices
More
